New Zealand defers decision on gout medicine

11 August 2021 - Deborah Wilkes

New Zealand's Medicines Classification Committee (MCC) has deferred a decision on an application to change the status of allopurinol for preventing gout, but has made recommendations on proposals involving choline salicylate, hyaluronidase and ibuprofen.